T-Cypher Bio

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. Our goals: - Develop next generation TCR therapies for treatment of cancer and autoimmune disease - Innovate to make TCR therapies widely available to patients About T-Cypher - Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder - Proprietary disease target and TCR discovery platform - Expanding TCR-bank against novel, differentiated targets - Differentiated approach to multiplexing TCRs in therapeutic T-cells - Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology